Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

AIntibody Test Results The AIntibody blind test involved 511 antibodies submitted by 29 organizations for three tasks, with independent laboratories synthesizing and testing them under the same conditions. An antibody is a protein that recognizes and binds to a specific target, requiring a strong bond, sufficient production, stable form, and selectivity to its target. The competition measured both the rare best result and the fraction of variants that a laboratory could work with further, using the logic of blind tests from CASP. The AIntibody competition continued from 2024, where participants submitted antibody sequences in advance, with all variants first tested using surface plasmon resonance to measure binding to the target, and the strongest further measured using KinExA. In the task of improving an already known antibody, a variant from company Aureka bound to the target as strongly as the best laboratory variant, with 94.7 versus 113 pM by KinExA, and their 95% uncertainty intervals overlapped. This was the result of one team in the task where participants were given data from the first stage of laboratory selection, with the target being the RBD of SARS-CoV-2. The results were published in Nature Biotechnology on August 19. 🔗 Read original →